We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proteins Linked to COVID-19-Associated Inflammatory Syndromes

By LabMedica International staff writers
Posted on 10 May 2022

COVID-19 associated acute respiratory distress syndrome (COVID-19 ARDS) is one of the major manifestations of the severe cases, characterized by hypoxemic respiratory failure with bilateral lung infiltrate, as well as multi-organ dysfunction and extensive microthrombus formation.

A minority of children with COVID-19 present with an unexplained multisystem inflammatory syndrome termed ‘multisystem inflammatory syndrome in children’ or MIS-C, also known as the Pediatric Multisystem Inflammatory Syndrome Temporally associated with SARS-CoV-2. Signs of MIS-C manifested 2 to 4 weeks after the SARS-CoV-2 infection, showing similar clinical features to Kawasaki disease and toxic shock syndrome.


Image: TripleTOF 6600+ System optimized for large-scale quantitative mass spectrometry and offers sensitive and robust quantitation using dedicated low flow source technology (Photo courtesy of Sciex)
Image: TripleTOF 6600+ System optimized for large-scale quantitative mass spectrometry and offers sensitive and robust quantitation using dedicated low flow source technology (Photo courtesy of Sciex)

A large team of Clinical Scientists at the Murdoch Children’s Research Institute (Melbourne, Australia) and their colleagues characterized the underlying mechanisms associated with severe COVID-19 phenotypes in children (MIS-C and COVID-19 ARDS) and how their plasma proteomic pathways differ from healthy children. Blood samples from SARS-CoV-2 infected children with MIS-C or COVID-19 ARDS were collected from children at the Necker–Enfants Malades Hospital (Paris, France) in 2020. Blood samples from healthy children were collected, processed and stored at −80 °C prior to the COVID-19 pandemic.

Mass Spectrometry proteomics to determine the plasma proteins expressed in healthy children pre-pandemic, children with multisystem inflammatory syndrome (MIS-C) and children with COVID-19 induced ARDS. Information Dependent Acquisition and SWATH Acquisition using a 6600 TripleTOF mass spectrometer (Sciex, Framingham, MA, USA) coupled to an Eksigent Ultra-nanoLC-1D system (Eksigent Technologies, Dublin, CA, USA) was employed for both IDA and SWATH-MS analysis.

The scientists uncovered 76 proteins that were differentially expressed across the groups as well as 85 proteins that were specific to MIS-C and 52 specific to ARDS. These protein sets highlighted the roles of the complement activation and coagulation pathways in both inflammatory syndromes as well as suggested the involvement of Fcγ receptor and B-cell receptor activation in MIS-C as well as heme scavenging and retinoid metabolism in COVID-19-related ARDS.

The authors conclude that they had observed complement activation and coagulation dysregulation in children with MIS-C and COVID-ARDS with additional contribution of FcGR and BCR activation in MIS-C and they suggest the scavenging of haem and retinoid metabolism in COVID-19 ARDS. The study was published on May 2, 2022 in the journal Nature Communications.

Related Links:
Murdoch Children’s Research Institute 
Necker–Enfants Malades Hospital 
Sciex 
Eksigent Technologies 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Coagulation Analyzer
CS-2400

Latest Clinical Chem. News

Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring

Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood



Sekisui Diagnostics UK Ltd.